Navigation Links
Poniard Pharmaceuticals Receives Going Concern Qualification
Date:3/16/2009

SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 16, 2009, contained a going concern qualification from its independent registered accounting firm, KPMG.

This announcement is required by Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification. This announcement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal cancer and castration-resistant prostate cancer (also known as hormone-refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
2. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores
7. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
8. Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
9. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
10. MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction ... at a time when Virginia faces an opioid epidemic. , Last ... increase of 38 percent from 2015, underscoring the need for additional addiction treatment ...
(Date:9/21/2017)... Fort Worth, TX (PRWEB) , ... September 21, ... ... top 50 senior housing operators, announces the acquisition of Isle at Kingwood Assisted ... Isle at Kingwood is an established retirement community with 55 assisted living apartments, ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... the Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the ... quick and easy access to essential information that offers a more comprehensive understanding ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... as one of the Best Places to Work in the Research Triangle for ... Workplace. Once nominated, a company had to meet a threshold in employee participation--a ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: